RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia

MLA

Guillermo Montalban-Bravo, et al. “RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia.” Blood, vol. 140, Nov. 2022, pp. 4036–38. EBSCOhost, https://doi.org/10.1182/blood-2022-170069.

APA

Guillermo Montalban-Bravo, Faezeh Darbaniyan, Kelly S. Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Farhad Ravandi, Elias Jabbour, Naveen Pemmaraju, Nicholas Short, Koichi Takahashi, Zeev E. Estrov, Sherry A. Pierce, Hagop Kantarjian, & Guillermo Garcia-Manero. (2022). RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia. Blood, 140, 4036–4038. https://doi.org/10.1182/blood-2022-170069

Chicago

Guillermo Montalban-Bravo, Faezeh Darbaniyan, Kelly S. Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Courtney D. DiNardo, et al. 2022. “RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia.” Blood 140 (November): 4036–38. doi:10.1182/blood-2022-170069.